This potential catalyst paired with the price target increase had traders eager to get their hands on shares of Protalix BioTherapeutics Inc. (NYSE American:PLX) as shares of the small cap reached $1.66/share (+11.41%) at the session high. This move could be an indication of things to come seeing how far off this stock is from it’s 52-week high, meaning that there is plenty of upside from current levels.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company’s products also treat diseases like Fabry disease and cystic fibrosis.The company’s primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
]]>